CompaniesAELIX Therapeutics

AELIX Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (3)
View all

Total Trials

3

As Lead Sponsor

2

As Collaborator

1

Total Enrollment

101

By Phase

PHASE1: 2PHASE2: 1

By Status

COMPLETED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
Today
NCT03204617
NCT04364035
NCT04385875
Hover over trial bars to see details

Recent Trials

NCT04385875Collaborator
Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)
PHASE1Completed
6 participants
Started: Jun 1, 2020 · Completed: Feb 10, 2022
NCT04364035Lead Sponsor
Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients
PHASE2Completed
50 participants
Started: Feb 20, 2020 · Completed: Dec 16, 2022
NCT03204617Lead Sponsor
Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)
PHASE1Completed
45 participants
Started: Jul 7, 2017 · Completed: Mar 10, 2021